THE ESTREET JOURNALNew Scientific Discovery Could Revolutionize The Global Medical Industry. Non-Medical Application Opportunities May Also Abound.
Bioelectromagnetics, many scientists believe, has emerged as the medicine of the twenty-first century. Bioelectromagnetics is the diagnostic and therapeutic use of electricity and magnetism on biological systems. In other words, the laws of physics applied to medical therapeutics. The growing body of knowledge, theoretical, experimental, and clinical, appears in an estimated ten thousand peer reviewed journal articles. Albert Einstein laid the groundwork for this promising new approach to the elimination of pain and to improved health.
Einstein, named Man of the Century, by Time magazine is considered by many to be the greatest scientist who ever lived. Yet, with all his contributions he could not find what he most sought-a unifying principal, a unified field of energy. He spent the last years of his life seeking this elusive principle.
Now, one man, Dr. Jerry I. Jacobson, believes he has found the Holy Grail of physics, the Unified Field Equation that links the forces of nature. He used the principle to create a machine that has the potential to treat numerous illnesses as well as having applications in the agricultural, construction, pharmaceutical, food and beverage, and environmental industries. The principle is called Jacobson Resonance. It is the basis of an emerging company: Jacobson Resonance Enterprises, Inc. (JRSE).
The first Jacobson Resonators were fabricated at NASA's Stennis Space Center's prototyping laboratories. The Company has developed four different models for research and clinical use. JRSE has ninety six issued, allowed, or pending worldwide patents, covering it's resonance technology, applications and methodology. The Company continues to file new patents aggressively.
FDA clearance for the Jacobson Resonator is anticipated in 2002. The FDA has already granted JRSE a letter of non-significant risk. On January 10th 2001 the Company received formal license issuance of the CE-Mark (the European equivalent of FDA), by the Health Authorities of the European Union for the medical use, distribution, manufacturing, and sale of Jacobson Resonators throughout the 15 nation members of the European Union. This approval covers the broad spectrum of chronic pain of the knees. Health Canada, on September 2001 extended licensing rights to treat "all types of pain" no matter the cause. These licensing rights include the commercialization and use of Jacobson Resonators in Canada and Europe and in other countries, which have reciprocity licenses in active trade agreements with both.
Medical Applications. The Company is planning to use Jacobson Resonance for the reduction of chronic and acute pain, including treatment of: Osteoarthritis Rheumatoid arthritis Lower back injuries Tendonitis Muscle spasms Sports injuries Carpal and Tarsi tunnel syndromes Neuropathy Migraine, tension, cluster, sinus, and menstrual headaches. Fibromyalgia
The medical market for Jacobson Resonance is vast. Based on data developed by the National Chronic Pain Outreach Association, an estimated 34 million people in the United States of America suffer from chronic pain and approximately 50 million workdays are lost annually because of chronic pain. Over $100 billion is spent on pain treatment each year in the USA alone.
Non-medical applications. Jacobson Resonance can restructure water molecules. Studies have demonstrated that resonated drinking water may improve digestion, speed absorption of nutrients in the gastrointestinal tract and provide ancillary benefits such as greater regularity, increased stamina and improved circulation. JRSE has executed a licensing agreement with RealPure Beverage Group for the use of Jacobson Resonance in multiple water and beverage production lines.
Other non-medical applications will include: Energy-efficient home water purification systems Increasing total weight of plants and fruits Enhancing growth cycles of fish and shell fish Rice farming Forestry and lumber operations Green house facilities Citrus production Wine production Landscaping.
Resonated water has been used to enhance the rate of growth and total plant weight in studies by Dr. Leonard Pike at Texas A & M. "It's mind-boggling what we can do," says Dr. Pike.
At Cornell University Medical College Dr. Brij Saxena successfully performed an in-vitro study, which resulted in significant peripheral nerve repair, growth, and regeneration in the sciatic nerves extracted from mice. At Mississippi State University College of Veterinary Medicine a pre-clinical in-vitro study using Jacobson Resonance impaired both the viability and proliferation rate of human mammary ductal carcinoma cells in tissue culture environments. A comprehensive annotated list of research studies is available from the company.
An industry-experienced management team, led by Dr. Jacobson, plans to capture a significant share of a vast market. If the Company were able to take even 1% of the pain treatment market over the next few years, it could produce a revenue stream of $1 billion in pain management alone.
Dr. Jerry I. Jacobson, the company's chairman, developed the technology on which the Company is based. When he was four years old, his father lost his larynx to cancer, and the son decided to devote his life to curing that disease. He was inspired in his youth by Albert Einstein, and is guided still by his words:
"In the middle of difficulty lies opportunity. The important thing is not to stop questioning." --Albert Einstein.
The quest for a cancer cure continues. Dramatic progress has been made. Jacobson said after the recent Mississippi University study cited above, "Jacobson Resonance may significantly reduce the required dose of conventional chemotherapy."
Jacobson Resonance continues to impact the medical sector as well as non-medical arenas. The potential for growth is tremendous.
[This message has been edited by cabbage22 (edited March 01, 2004).]
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
